DE69427862D1 - K-252a derivate, die neurotrophin-induzierte aktivität erhöhen - Google Patents

K-252a derivate, die neurotrophin-induzierte aktivität erhöhen

Info

Publication number
DE69427862D1
DE69427862D1 DE69427862T DE69427862T DE69427862D1 DE 69427862 D1 DE69427862 D1 DE 69427862D1 DE 69427862 T DE69427862 T DE 69427862T DE 69427862 T DE69427862 T DE 69427862T DE 69427862 D1 DE69427862 D1 DE 69427862D1
Authority
DE
Germany
Prior art keywords
derivatives
induced activity
neurotrophin
increase
increase neurotrophin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69427862T
Other languages
English (en)
Other versions
DE69427862T2 (de
Inventor
A Glicksman
P Rotella
Nicola Neff
Chikara Murakata
L Hudkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Cephalon LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of DE69427862D1 publication Critical patent/DE69427862D1/de
Application granted granted Critical
Publication of DE69427862T2 publication Critical patent/DE69427862T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69427862T 1993-09-16 1994-09-16 K-252a derivate, die neurotrophin-induzierte aktivität erhöhen Expired - Fee Related DE69427862T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/122,893 US5468872A (en) 1993-09-16 1993-09-16 K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
PCT/US1994/010495 WO1995007911A1 (en) 1993-09-16 1994-09-16 K-252a DERIVATIVES WHICH ENHANCE NEUROTROPHIN-INDUCED ACTIVITY

Publications (2)

Publication Number Publication Date
DE69427862D1 true DE69427862D1 (de) 2001-09-06
DE69427862T2 DE69427862T2 (de) 2002-04-11

Family

ID=22405467

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69427862T Expired - Fee Related DE69427862T2 (de) 1993-09-16 1994-09-16 K-252a derivate, die neurotrophin-induzierte aktivität erhöhen

Country Status (14)

Country Link
US (2) US5468872A (de)
EP (1) EP0719268B1 (de)
JP (2) JP3943126B2 (de)
KR (1) KR100186912B1 (de)
AT (1) ATE203751T1 (de)
AU (1) AU693480B2 (de)
CA (1) CA2171561C (de)
DE (1) DE69427862T2 (de)
ES (1) ES2160637T3 (de)
FI (1) FI961236A0 (de)
HU (1) HU222570B1 (de)
NO (1) NO309228B1 (de)
NZ (2) NZ274355A (de)
WO (1) WO1995007911A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2123096A1 (en) * 1991-11-08 1993-05-13 Beat J. Knusel Compositions containing k-252 compounds for potentiation of neurotrophin activity
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
EP0675125A1 (de) * 1994-03-18 1995-10-04 Kyowa Hakko Kogyo Co., Ltd. Therapeutisches Mittel für Thrombozytopenie und Indolocarbazol-Derivate
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
WO1997005140A1 (en) * 1995-07-31 1997-02-13 Novartis Ag Trindene compounds
AU6733996A (en) * 1995-07-31 1997-02-26 Ciba-Geigy Ag Staurosporine analogues
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
CA2315953C (en) 1997-12-31 2010-11-09 Cephalon, Inc. 3'-epimeric k-252a derivatives
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
AU763435B2 (en) 1998-09-25 2003-07-24 Cephalon, Inc. Methods for preventing/treating damage to sensory hair cells and cochlear neurons
EP1101113A4 (de) * 1999-06-09 2002-05-08 Ljl Biosystems Inc Verfahren zum messen von zellsignalen
WO2001010440A1 (en) * 1999-08-09 2001-02-15 Trustees Of Dartmouth College COMPOSITIONS AND METHODS TO ENHANCE CANCER CHEMOTHERAPY IN p53 DEFECTIVE TUMORS
FR2798931B1 (fr) 1999-09-22 2001-11-16 Oreal Nouveaux composes indoliques, leur utilisation pour la teinture et le maquillage des matieres keratiniques, compositions les contenant et procedes de teinture
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US6555677B2 (en) 2000-10-31 2003-04-29 Merck & Co., Inc. Phase transfer catalyzed glycosidation of an indolocarbazole
RU2003131269A (ru) 2001-03-22 2005-05-10 Бристол-Маерс Сквибб Компани (Us) Производные индолопирролокарбазолов и сахаров, цитотоксические и селективные по отношению к топоизомеразе i
AR035971A1 (es) * 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
US20040186044A1 (en) * 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
WO2004056385A2 (en) 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
BRPI0408501A (pt) 2003-03-19 2006-03-14 Biogen Idec Inc proteìna de ligação ao receptor nogo
PL1776136T3 (pl) 2004-06-24 2013-03-29 Biogen Ma Inc Leczenie stanów związanych z demielinizacją
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
RS53058B (en) 2005-07-08 2014-04-30 Biogen Idec Ma Inc. SP35 ANTIBODIES AND THEIR APPLICATIONS
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
PT2120997T (pt) * 2006-12-21 2017-05-05 H Lundbeck As Modulação da atividade de proneurotrofinas
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
ES2326459B1 (es) 2008-04-08 2010-05-28 Universidad De Oviedo Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos.
EP2982695B1 (de) 2008-07-09 2019-04-03 Biogen MA Inc. Zusammensetzungen mit antikörpern gegen lingo oder fragmenten davon
EP2381964B1 (de) 2008-12-22 2014-06-25 Creabilis S.a. Synthese von polymerkonjugaten von indolocarbazol-verbindungen
CN103242404A (zh) * 2012-02-03 2013-08-14 复旦大学 N-鼠李糖基苯并咔唑化合物及其合成方法和在制药中的用途
AU2013262934B2 (en) 2012-05-14 2018-02-01 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
CN103012417B (zh) * 2013-01-08 2015-01-07 中国科学院昆明植物研究所 黄皮属植物中的咔唑生物碱,以其为抗肿瘤活性成分的药物组合物,其制备方法和应用
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60257652A (ja) * 1984-06-02 1985-12-19 Canon Inc 画像処理装置
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4735939A (en) * 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
DE3752123T2 (de) * 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
DE3835842A1 (de) * 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5231001A (en) * 1991-03-14 1993-07-27 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
JPH06509333A (ja) * 1991-07-03 1994-10-20 リジェネロン　ファーマシューティカルズ，インコーポレーテッド ニューロトロフィン活性に対する方法およびアッセイ系
CA2123096A1 (en) * 1991-11-08 1993-05-13 Beat J. Knusel Compositions containing k-252 compounds for potentiation of neurotrophin activity
JPH05247056A (ja) * 1992-03-03 1993-09-24 Kyowa Hakko Kogyo Co Ltd インドロカルバゾール誘導体
DE4217963A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Verwendung von Indolocarbazolen zur Behandlung von AIDS
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders

Also Published As

Publication number Publication date
NO309228B1 (no) 2001-01-02
NO961087D0 (no) 1996-03-15
EP0719268A1 (de) 1996-07-03
US5468872A (en) 1995-11-21
HU222570B1 (hu) 2003-08-28
EP0719268B1 (de) 2001-08-01
FI961236A (fi) 1996-03-15
HUT74679A (en) 1997-01-28
DE69427862T2 (de) 2002-04-11
US5516772A (en) 1996-05-14
HU9600657D0 (en) 1996-05-28
NO961087L (no) 1996-05-13
FI961236A0 (fi) 1996-03-15
JP3943126B2 (ja) 2007-07-11
ES2160637T3 (es) 2001-11-16
JP2005220141A (ja) 2005-08-18
CA2171561C (en) 1999-08-03
WO1995007911A1 (en) 1995-03-23
NZ314037A (en) 2000-09-29
KR100186912B1 (ko) 1999-05-01
ATE203751T1 (de) 2001-08-15
KR960704894A (ko) 1996-10-09
AU7836394A (en) 1995-04-03
NZ274355A (en) 1997-03-24
AU693480B2 (en) 1998-07-02
CA2171561A1 (en) 1995-03-23
JPH09502730A (ja) 1997-03-18

Similar Documents

Publication Publication Date Title
ATE203751T1 (de) K-252a derivate, die neurotrophin-induzierte aktivität erhöhen
DE69825048D1 (de) Analoga von duocarmycin and cc-1065
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
ES2138622T3 (es) Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
ITMI930699A1 (it) Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
BR9707659A (pt) Pirrol(2,3-C) carbarzol-6-onas que potencializam atividade atividade de interferon gama
MX9302414A (es) Proceso para la fabricacion de pirrolidinas (s)-3-amino-1- substituidas.
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
ES2062145T3 (es) 1,8-naftiridinas substituidas.
BR9406034A (pt) Derivados de imidazoloquinoxalinonas como antagonistas de eaa.
AU7025087A (en) Pharmaceutical compositions for the therapy of cerebropathies on functional and organic base
ES2056876T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
MX9307679A (es) Derivados de furanona utiles en terapia.
FR2697253B1 (fr) Dérivés de 2-aminopyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique.
ZA893606B (en) Use of diazepinones for treating disorders of the microcirculation
LV5780B4 (lv) Pretkonvulsiji triazolÚ4,5-c¾piridina atvasinajumi
FR2703355B1 (fr) Dérivés de 2-aminopyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique.
FR2714058B1 (fr) Dérivés de 1,3-dioxane trisubstitués, leur préparation et leur application en thérapeutique.
FR2698364B1 (fr) Dérivés de pyrrole, leur préparation et leur application en thérapeutique.
FI881534A0 (fi) Ljuddaempare foer daempning av oljud i ventilationsanordning.
FI870519A0 (fi) Ljuddaempare foer daempning av oljud i ventilationsanordning.
MX5313A (es) Derivados heterociclicos para el tratamiento de trastornos cardiovasculares y procedimiento para obtenerlos.
FR2707987B1 (fr) Dérivés de 9H-imidazo[1,2-a]benzimidazole-3-acétamide, leur préparation et leur application en thérapeutique .

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee